Ascendis Pharma stock tumbled Wednesday after the firm cut its outlook for its human growth hormone amid market-wide price struggles.

The post Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout appeared first on Investor’s Business Daily.